Prophylactic occludin-derived peptide reduces airway inflammation and enhances barrier function, indicating a potential treatment for lung diseases.
Occludin is a key tight junction protein that contributes to epithelial barrier integrity and inflammatory regulation. Although its structural roles are well characterized, the physiological relevance of its C-terminal domain in airway inflammation remains poorly defined. Occludin expression was statistically reduced in inflamed human lung tissues. In BEAS-2B cells, occludin overexpression suppressed LPS-induced IL-8 release, restored barrier integrity, and reduced F-actin remodeling, whereas C-terminal deletion abolished these effects. The C-terminal occludin peptide (391∼412) significantly decreased IL-8 production, improved barrier function, and suppressed cytoskeletal changes, while a mutant peptide was ineffective. Transcriptomic analyses identified occludin as a central suppressor of inflammatory signaling. Mechanistically, the peptide inhibited p38 activation, preserved mitochondrial structure, and reduced mtROS production. In vivo , peptide pretreatment improved survival, lowered IL-1β, IL-6, IL-8, and TNF-α levels, and reduced goblet cell hyperplasia and inflammatory infiltration. Immune profiling further revealed restored T-cell populations, reduced myeloid expansion, and enhanced M2 alveolar macrophage polarization. The occludin C-terminal–derived peptide exerts robust anti-inflammatory, barrier-protective effects, and a modulator of mitochondrial redox balance representing a promising therapeutic candidate for LPS-induced and potentially broader inflammatory lung diseases. • Occludin expression is significantly reduced in inflamed human lung tissues. • A synthetic peptide derived from the occludin C-terminal region effectively reduces LPS-induced inflammation. • Occludin C-terminal peptide improves survival, decreases pro-inflammatory cytokines, reduces pathological lung changes, and rebalances redox homeostasis, and promoting M2 alveolar macrophage polarization.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: